The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

• Main Authors: Joon Hyung Kim (Author), John Diaz-Decaro (Author), Ning Jiang (Author), Shinn-Jang Hwang (Author), Eun Ju Choo (Author), Maribel Co (Author), Andrew Hastie (Author), David Shu Cheong Hui (Author), Junya Irimajiri (Author), Jacob Lee (Author), Edward Man-Fuk Leung (Author), Haiwen Tang (Author), Tomomi Tsuru (Author), Philip Watson (Author), Zhenhua Wu (Author), Chong-Jen Yu (Author), Yanfei Yuan (Author), Toufik Zahaf (Author), Anthony L. Cunningham (Author), Anne Schuind (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc analysis assessed the VE against HZ and postherpeti...